Dermatology Clinical Trials Unit
The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allows our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for psoriasis, skin cancer, and acne. The trials unit draws on the dermatology division's vast clinical experience (over 30,000 patient visits annually).
Current Clinical Trials
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate to Severe Atopic Dermatitis.
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients with Persistent Moderate to Severe Atopic Dermatitis that is Inadequately Controlled by Topical Corticosteroids.
A Phase 3 Multicenter, Randomized, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 and Fluoroscent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma.
For further information on any of these trials,
Clinical Research Coordinator
Tel: (314) 362-8171